Skip to main content
Top
Published in: Cancer and Metastasis Reviews 2-3/2014

01-09-2014

Integrating new discoveries into the “vicious cycle” paradigm of prostate to bone metastases

Authors: Leah M. Cook, Gemma Shay, Arturo Aruajo, Conor C. Lynch

Published in: Cancer and Metastasis Reviews | Issue 2-3/2014

Login to get access

Abstract

In prostate to bone metastases, the “vicious cycle” paradigm has been traditionally used to illustrate how metastases manipulate the bone forming osteoblasts and resorbing osteoclasts in order to yield factors that facilitate growth and establishment. However, recent advances have illustrated that the cycle is far more complex than this simple interpretation. In this review, we will discuss the role of exosomes and hematopoietic/mesenchymal stem/stromal cells (MSC) that facilitate the establishment and activation of prostate metastases and how cells including myeloid-derived suppressor cells, macrophages, T cells, and nerve cells contribute to the momentum of the vicious cycle. The increased complexity of the tumor–bone microenvironment requires a system level approach. The evolution of computational models to interrogate the tumor–bone microenvironment is also discussed, and the application of this integrated approach should allow for the development of effective therapies to treat and cure prostate to bone metastases.
Literature
1.
go back to reference Keller, E. T., & Brown, J. (2004). Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Journal of Cellular Biochemistry, 91(4), 718–729.PubMed Keller, E. T., & Brown, J. (2004). Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Journal of Cellular Biochemistry, 91(4), 718–729.PubMed
2.
go back to reference Fizazi, K., et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377(9768), 813–822.PubMedCentralPubMed Fizazi, K., et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377(9768), 813–822.PubMedCentralPubMed
3.
go back to reference Choudhury, A. D., & Kantoff, P. W. (2012). New agents in metastatic prostate cancer. Journal of the National Comprehensive Cancer Network, 10(11), 1403–1409.PubMed Choudhury, A. D., & Kantoff, P. W. (2012). New agents in metastatic prostate cancer. Journal of the National Comprehensive Cancer Network, 10(11), 1403–1409.PubMed
4.
go back to reference Anonymous. (2013). FDA approves radiopharmaceutical for metastatic prostate cancer. Cancer Discovery, 3(7), OF1. Anonymous. (2013). FDA approves radiopharmaceutical for metastatic prostate cancer. Cancer Discovery, 3(7), OF1.
5.
go back to reference Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews, 8(2), 98–101.PubMed Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews, 8(2), 98–101.PubMed
6.
go back to reference Lu, X., et al. (2011). VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell, 20(6), 701–714.PubMedCentralPubMed Lu, X., et al. (2011). VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell, 20(6), 701–714.PubMedCentralPubMed
7.
go back to reference Kang, Y., et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3(6), 537–549.PubMed Kang, Y., et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 3(6), 537–549.PubMed
8.
go back to reference Sun, Y. X., et al. (2005). Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 20(2), 318–329. Sun, Y. X., et al. (2005). Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 20(2), 318–329.
9.
go back to reference Kaplan, R. N., Psaila, B., & Lyden, D. (2006). Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Reviews, 25(4), 521–529.PubMed Kaplan, R. N., Psaila, B., & Lyden, D. (2006). Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Reviews, 25(4), 521–529.PubMed
10.
go back to reference Kaplan, R. N., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069), 820–827.PubMedCentralPubMed Kaplan, R. N., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069), 820–827.PubMedCentralPubMed
11.
go back to reference Kaplan, R. N., Psaila, B., & Lyden, D. (2007). Niche-to-niche migration of bone-marrow-derived cells. Trends in Molecular Medicine, 13(2), 72–81.PubMed Kaplan, R. N., Psaila, B., & Lyden, D. (2007). Niche-to-niche migration of bone-marrow-derived cells. Trends in Molecular Medicine, 13(2), 72–81.PubMed
12.
go back to reference Janowska-Wieczorek, A., et al. (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. International Journal of Cancer, 113(5), 752–760. Janowska-Wieczorek, A., et al. (2005). Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. International Journal of Cancer, 113(5), 752–760.
13.
go back to reference Peinado, H., et al. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 18(6), 883–891.PubMedCentralPubMed Peinado, H., et al. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 18(6), 883–891.PubMedCentralPubMed
14.
go back to reference Pan, B. T., et al. (1985). Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. The Journal of Cell Biology, 101(3), 942–948.PubMed Pan, B. T., et al. (1985). Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. The Journal of Cell Biology, 101(3), 942–948.PubMed
15.
go back to reference Couzin, J. (2005). Cell biology: the ins and outs of exosomes. Science, 308(5730), 1862–1863.PubMed Couzin, J. (2005). Cell biology: the ins and outs of exosomes. Science, 308(5730), 1862–1863.PubMed
16.
go back to reference Johnstone, R. M., et al. (1987). Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). Journal of Biological Chemistry, 262(19), 9412–9420.PubMed Johnstone, R. M., et al. (1987). Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). Journal of Biological Chemistry, 262(19), 9412–9420.PubMed
17.
go back to reference Thery, C., Zitvogel, L., & Amigorena, S. (2002). Exosomes: composition, biogenesis and function. Nature Reviews Immunology, 2(8), 569–579.PubMed Thery, C., Zitvogel, L., & Amigorena, S. (2002). Exosomes: composition, biogenesis and function. Nature Reviews Immunology, 2(8), 569–579.PubMed
18.
go back to reference Schara, K., et al. (2009). Mechanisms for the formation of membranous nanostructures in cell-to-cell communication. Cellular & Molecular Biology Letters, 14(4), 636–656. Schara, K., et al. (2009). Mechanisms for the formation of membranous nanostructures in cell-to-cell communication. Cellular & Molecular Biology Letters, 14(4), 636–656.
19.
go back to reference Ostrowski, M., et al. (2010). Rab27a and Rab27b control different steps of the exosome secretion pathway. Nature Cell Biology, 12(1), 19–30. sup pp 1–13.PubMed Ostrowski, M., et al. (2010). Rab27a and Rab27b control different steps of the exosome secretion pathway. Nature Cell Biology, 12(1), 19–30. sup pp 1–13.PubMed
20.
go back to reference Knudsen, B. S., & Edlund, M. (2004). Prostate cancer and the met hepatocyte growth factor receptor. Advances in Cancer Research, 91, 31–67.PubMed Knudsen, B. S., & Edlund, M. (2004). Prostate cancer and the met hepatocyte growth factor receptor. Advances in Cancer Research, 91, 31–67.PubMed
21.
go back to reference Di Vizio, D., et al. (2012). Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. American Journal of Pathology, 181(5), 1573–1584.PubMedCentralPubMed Di Vizio, D., et al. (2012). Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. American Journal of Pathology, 181(5), 1573–1584.PubMedCentralPubMed
22.
go back to reference Webber, J., et al. (2010). Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Research, 70(23), 9621–9630.PubMed Webber, J., et al. (2010). Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Research, 70(23), 9621–9630.PubMed
23.
go back to reference Itoh, T., et al. (2012). Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation. Journal of Molecular Histology, 43(5), 509–515.PubMedCentralPubMed Itoh, T., et al. (2012). Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation. Journal of Molecular Histology, 43(5), 509–515.PubMedCentralPubMed
24.
go back to reference Lee, R. J., et al. (2013). A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(11), 3088–3094. Lee, R. J., et al. (2013). A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(11), 3088–3094.
25.
go back to reference Zhang, G., et al. (2012). A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nature Medicine, 18(2), 307–314.PubMed Zhang, G., et al. (2012). A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nature Medicine, 18(2), 307–314.PubMed
26.
go back to reference Chen, Q., & Massague, J. (2012). Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clinical Cancer Research, 18(20), 5520–5525.PubMedCentralPubMed Chen, Q., & Massague, J. (2012). Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clinical Cancer Research, 18(20), 5520–5525.PubMedCentralPubMed
27.
go back to reference Chen, Q., Zhang, X. H., & Massague, J. (2011). Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell, 20(4), 538–549.PubMedCentralPubMed Chen, Q., Zhang, X. H., & Massague, J. (2011). Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell, 20(4), 538–549.PubMedCentralPubMed
28.
go back to reference Spain, L. M., & Mulligan, R. C. (1992). Purification and characterization of retrovirally transduced hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 89(9), 3790–3794.PubMedCentralPubMed Spain, L. M., & Mulligan, R. C. (1992). Purification and characterization of retrovirally transduced hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 89(9), 3790–3794.PubMedCentralPubMed
29.
go back to reference Matsuzaki, Y., et al. (2004). Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. Immunity, 20(1), 87–93.PubMed Matsuzaki, Y., et al. (2004). Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. Immunity, 20(1), 87–93.PubMed
30.
go back to reference Levesque, J. P., Helwani, F. M., & Winkler, I. G. (2010). The endosteal ‘osteoblastic’ niche and its role in hematopoietic stem cell homing and mobilization. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK, 24(12), 1979–1992. Levesque, J. P., Helwani, F. M., & Winkler, I. G. (2010). The endosteal ‘osteoblastic’ niche and its role in hematopoietic stem cell homing and mobilization. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK, 24(12), 1979–1992.
31.
go back to reference Heissig, B., et al. (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 109(5), 625–637.PubMedCentralPubMed Heissig, B., et al. (2002). Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell, 109(5), 625–637.PubMedCentralPubMed
32.
go back to reference Wang, Q., et al. (2013). SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene, 32(19), 2493–2498.PubMed Wang, Q., et al. (2013). SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene, 32(19), 2493–2498.PubMed
33.
go back to reference Taichman, R. S., et al. (2002). Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Research, 62(6), 1832–1837.PubMed Taichman, R. S., et al. (2002). Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Research, 62(6), 1832–1837.PubMed
34.
go back to reference Yu, C., et al. (2012). Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Critical Reviews in Eukaryotic Gene Expression, 22(2), 131–148.PubMedCentralPubMed Yu, C., et al. (2012). Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Critical Reviews in Eukaryotic Gene Expression, 22(2), 131–148.PubMedCentralPubMed
35.
go back to reference Shiozawa, Y., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. Journal of Clinical Investigation, 121(4), 1298–1312.PubMedCentralPubMed Shiozawa, Y., et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. Journal of Clinical Investigation, 121(4), 1298–1312.PubMedCentralPubMed
36.
go back to reference Joseph, J., et al. (2012). Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Molecular Cancer Research, 10(3), 282–292.PubMedCentralPubMed Joseph, J., et al. (2012). Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Molecular Cancer Research, 10(3), 282–292.PubMedCentralPubMed
37.
go back to reference Kim, S. W., et al. (2011). Consistent interactions between tumor cell IL-6 and macrophage TNF-alpha enhance the growth of human prostate cancer cells in the bone of nude mouse. International Immunopharmacology, 11(7), 862–872.PubMed Kim, S. W., et al. (2011). Consistent interactions between tumor cell IL-6 and macrophage TNF-alpha enhance the growth of human prostate cancer cells in the bone of nude mouse. International Immunopharmacology, 11(7), 862–872.PubMed
38.
go back to reference Rojas, A., et al. (2011). IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene, 30(20), 2345–2355.PubMedCentralPubMed Rojas, A., et al. (2011). IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene, 30(20), 2345–2355.PubMedCentralPubMed
39.
go back to reference Pusic, I., & DiPersio, J. F. (2010). Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Current Opinion in Hematology, 17(4), 319–326.PubMed Pusic, I., & DiPersio, J. F. (2010). Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Current Opinion in Hematology, 17(4), 319–326.PubMed
40.
go back to reference de Nigris, F., et al. (2012). CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Patents on Anti-Cancer Drug Discovery, 7(3), 251–264.PubMed de Nigris, F., et al. (2012). CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Patents on Anti-Cancer Drug Discovery, 7(3), 251–264.PubMed
41.
go back to reference Peng, Y., et al. (2012). Peroxisome proliferator-activated receptor alpha plays an important role in the expression of monocyte chemoattractant protein-1 and neointimal hyperplasia after vascular injury. PPAR Research, 2012, 970525.PubMedCentralPubMed Peng, Y., et al. (2012). Peroxisome proliferator-activated receptor alpha plays an important role in the expression of monocyte chemoattractant protein-1 and neointimal hyperplasia after vascular injury. PPAR Research, 2012, 970525.PubMedCentralPubMed
42.
go back to reference Li, T., & Wu, Y. (2011). Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche. Bone Marrow Research, 2011, 353878.PubMedCentralPubMed Li, T., & Wu, Y. (2011). Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche. Bone Marrow Research, 2011, 353878.PubMedCentralPubMed
43.
go back to reference Pittenger, M. F., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411), 143–147.PubMed Pittenger, M. F., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411), 143–147.PubMed
44.
go back to reference Karnoub, A. E., et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449(7162), 557–563.PubMed Karnoub, A. E., et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449(7162), 557–563.PubMed
45.
go back to reference El-Haibi, C. P., et al. (2012). Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A, 109(43), 17460–17465.PubMedCentralPubMed El-Haibi, C. P., et al. (2012). Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A, 109(43), 17460–17465.PubMedCentralPubMed
46.
go back to reference Jung, Y., et al. (2013). Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature Communications, 4, 1795.PubMedCentralPubMed Jung, Y., et al. (2013). Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature Communications, 4, 1795.PubMedCentralPubMed
47.
go back to reference Spaeth, E. L., et al. (2013) Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Research, 73, 5347–5359. Spaeth, E. L., et al. (2013) Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Research, 73, 5347–5359.
48.
go back to reference Yuen, H. F., et al. (2008). TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction. Carcinogenesis, 29(8), 1509–1518.PubMed Yuen, H. F., et al. (2008). TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction. Carcinogenesis, 29(8), 1509–1518.PubMed
49.
go back to reference Lee, T. K., et al. (2006). Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial–mesenchymal transition. Clinical Cancer Research, 12(18), 5369–5376.PubMed Lee, T. K., et al. (2006). Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial–mesenchymal transition. Clinical Cancer Research, 12(18), 5369–5376.PubMed
50.
go back to reference Otsu, K., et al. (2009). Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood, 113(18), 4197–4205.PubMedCentralPubMed Otsu, K., et al. (2009). Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood, 113(18), 4197–4205.PubMedCentralPubMed
51.
go back to reference Wang, M., et al. (2007). STAT3 mediates bone marrow mesenchymal stem cell VEGF production. Journal of Molecular and Cellular Cardiology, 42(6), 1009–1015.PubMedCentralPubMed Wang, M., et al. (2007). STAT3 mediates bone marrow mesenchymal stem cell VEGF production. Journal of Molecular and Cellular Cardiology, 42(6), 1009–1015.PubMedCentralPubMed
52.
go back to reference Liu, Y., et al. (2012). Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. Journal of Clinical Investigation, 122(9), 3101–3113.PubMedCentralPubMed Liu, Y., et al. (2012). Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. Journal of Clinical Investigation, 122(9), 3101–3113.PubMedCentralPubMed
53.
go back to reference Okuyama, H., et al. (2006). Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. Journal of Biological Chemistry, 281(22), 15554–15563.PubMed Okuyama, H., et al. (2006). Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. Journal of Biological Chemistry, 281(22), 15554–15563.PubMed
54.
go back to reference Qiao, L., et al. (2008). Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Letters, 269(1), 67–77.PubMed Qiao, L., et al. (2008). Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Letters, 269(1), 67–77.PubMed
55.
go back to reference Thudi, N. K., et al. (2011). Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate, 71(6), 615–625.PubMedCentralPubMed Thudi, N. K., et al. (2011). Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate, 71(6), 615–625.PubMedCentralPubMed
56.
go back to reference Bianco, P., et al. (2013). The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nature Medicine, 19(1), 35–42.PubMedCentralPubMed Bianco, P., et al. (2013). The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nature Medicine, 19(1), 35–42.PubMedCentralPubMed
57.
go back to reference Zheng, D., et al. (2013). Role of WNT7B-induced noncanonical pathway in advanced prostate cancer. Molecular Cancer Research, 11(5), 482–493.PubMed Zheng, D., et al. (2013). Role of WNT7B-induced noncanonical pathway in advanced prostate cancer. Molecular Cancer Research, 11(5), 482–493.PubMed
58.
go back to reference Hoda, M. R., et al. (2012). The adipocyte-derived hormone leptin has proliferative actions on androgen-resistant prostate cancer cells linking obesity to advanced stages of prostate cancer. Journal of Oncology, 2012, 280386.PubMedCentralPubMed Hoda, M. R., et al. (2012). The adipocyte-derived hormone leptin has proliferative actions on androgen-resistant prostate cancer cells linking obesity to advanced stages of prostate cancer. Journal of Oncology, 2012, 280386.PubMedCentralPubMed
59.
60.
go back to reference Sennino, B., et al. (2013). Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Research, 73(12), 3692–3703.PubMedCentralPubMed Sennino, B., et al. (2013). Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Research, 73(12), 3692–3703.PubMedCentralPubMed
61.
go back to reference Sennino, B., et al. (2012). Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discovery, 2(3), 270–287.PubMedCentralPubMed Sennino, B., et al. (2012). Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discovery, 2(3), 270–287.PubMedCentralPubMed
62.
go back to reference Lee, R. J., & Smith, M. R. (2013). Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer Journal, 19(1), 90–98. Lee, R. J., & Smith, M. R. (2013). Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer Journal, 19(1), 90–98.
63.
go back to reference Chanda, D., et al. (2009). Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 15(23), 7175–7185. Chanda, D., et al. (2009). Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 15(23), 7175–7185.
64.
go back to reference Kusmartsev, S., et al. (2004). Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. Journal of Immunology, 172(2), 989–999. Kusmartsev, S., et al. (2004). Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. Journal of Immunology, 172(2), 989–999.
65.
go back to reference Ueha, S., Shand, F. H., & Matsushima, K. (2011). Myeloid cell population dynamics in healthy and tumor-bearing mice. International Immunopharmacology, 11(7), 783–788.PubMed Ueha, S., Shand, F. H., & Matsushima, K. (2011). Myeloid cell population dynamics in healthy and tumor-bearing mice. International Immunopharmacology, 11(7), 783–788.PubMed
66.
go back to reference Lechner, M. G., Liebertz, D. J., & Epstein, A. L. (2010). Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. Journal of Immunology, 185(4), 2273–2284. Lechner, M. G., Liebertz, D. J., & Epstein, A. L. (2010). Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. Journal of Immunology, 185(4), 2273–2284.
67.
go back to reference Melani, C., et al. (2003). Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood, 102(6), 2138–2145.PubMed Melani, C., et al. (2003). Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood, 102(6), 2138–2145.PubMed
68.
go back to reference Yang, L., Edwards, C. M., & Mundy, G. R. (2010). Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 25(8), 1701–1706. Yang, L., Edwards, C. M., & Mundy, G. R. (2010). Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 25(8), 1701–1706.
69.
go back to reference Yang, L., et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6(4), 409–421.PubMed Yang, L., et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6(4), 409–421.PubMed
70.
go back to reference Sawant, A., et al. (2013). Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Research, 73(2), 672–682.PubMedCentralPubMed Sawant, A., et al. (2013). Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Research, 73(2), 672–682.PubMedCentralPubMed
71.
go back to reference Zhuang, J., et al. (2012). Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells. PLoS One, 7(11), e48871.PubMedCentralPubMed Zhuang, J., et al. (2012). Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells. PLoS One, 7(11), e48871.PubMedCentralPubMed
72.
go back to reference Danilin, S., et al. (2012). Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology, 1(9), 1484–1494.PubMedCentralPubMed Danilin, S., et al. (2012). Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Oncoimmunology, 1(9), 1484–1494.PubMedCentralPubMed
73.
go back to reference Pang, Y., et al. (2013). TGF-beta signaling in myeloid cells is required for tumor metastasis. Cancer Discovery, 3(8), 936–951.PubMed Pang, Y., et al. (2013). TGF-beta signaling in myeloid cells is required for tumor metastasis. Cancer Discovery, 3(8), 936–951.PubMed
74.
go back to reference Nefedova, Y., et al. (2007). Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Research, 67(22), 11021–11028.PubMed Nefedova, Y., et al. (2007). Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Research, 67(22), 11021–11028.PubMed
75.
go back to reference Fujita, M., et al. (2011). COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Research, 71(7), 2664–2674.PubMedCentralPubMed Fujita, M., et al. (2011). COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Research, 71(7), 2664–2674.PubMedCentralPubMed
76.
go back to reference Suzuki, E., et al. (2005). Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research, 11(18), 6713–6721.PubMed Suzuki, E., et al. (2005). Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research, 11(18), 6713–6721.PubMed
77.
go back to reference Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology, 12(4), 253–268.PubMedCentralPubMed Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology, 12(4), 253–268.PubMedCentralPubMed
78.
go back to reference Iclozan, C., et al. (2013). Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunology, Immunotherapy : CII, 62(5), 909–918.PubMedCentralPubMed Iclozan, C., et al. (2013). Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunology, Immunotherapy : CII, 62(5), 909–918.PubMedCentralPubMed
79.
go back to reference Qian, B. Z., & Pollard, J. W. (2012). New tricks for metastasis-associated macrophages. Breast Cancer Research, 14(4), 316.PubMedCentralPubMed Qian, B. Z., & Pollard, J. W. (2012). New tricks for metastasis-associated macrophages. Breast Cancer Research, 14(4), 316.PubMedCentralPubMed
80.
go back to reference Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9(4), 239–252.PubMedCentralPubMed Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9(4), 239–252.PubMedCentralPubMed
81.
go back to reference Glofcheskie, B. D., & Surgeoner, G. A. (1990). Muscovy ducks as an adjunct for the control of the house fly (Diptera: Muscidae). Journal of Economic Entomology, 83(3), 788–791.PubMed Glofcheskie, B. D., & Surgeoner, G. A. (1990). Muscovy ducks as an adjunct for the control of the house fly (Diptera: Muscidae). Journal of Economic Entomology, 83(3), 788–791.PubMed
82.
go back to reference Dirkx, A. E., et al. (2006). Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 80(6), 1183–1196.PubMed Dirkx, A. E., et al. (2006). Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 80(6), 1183–1196.PubMed
83.
go back to reference Alexander, K. A., et al. (2011). Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 26(7), 1517–1532. Alexander, K. A., et al. (2011). Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 26(7), 1517–1532.
84.
go back to reference Mizutani, K., et al. (2009). The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia, 11(11), 1235–1242.PubMedCentralPubMed Mizutani, K., et al. (2009). The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia, 11(11), 1235–1242.PubMedCentralPubMed
85.
go back to reference Herroon, M. K., et al. (2013). Macrophage cathepsin K promotes prostate tumor progression in bone. Oncogene, 32(12), 1580–1593.PubMedCentralPubMed Herroon, M. K., et al. (2013). Macrophage cathepsin K promotes prostate tumor progression in bone. Oncogene, 32(12), 1580–1593.PubMedCentralPubMed
86.
go back to reference Lin, T. H., et al. (2013). CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration. Biochimica et Biophysica Acta, 1830(10), 4917–4927.PubMed Lin, T. H., et al. (2013). CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration. Biochimica et Biophysica Acta, 1830(10), 4917–4927.PubMed
87.
go back to reference Loberg, R. D., et al. (2007). Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Research, 67(19), 9417–9424.PubMed Loberg, R. D., et al. (2007). Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Research, 67(19), 9417–9424.PubMed
88.
go back to reference Loberg, R. D., et al. (2007). CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia, 9(7), 556–562.PubMedCentralPubMed Loberg, R. D., et al. (2007). CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia, 9(7), 556–562.PubMedCentralPubMed
89.
go back to reference Hagemann, T., et al. (2008). “Re-educating” tumor-associated macrophages by targeting NF-kappaB. Journal of Experimental Medicine, 205(6), 1261–1268.PubMedCentralPubMed Hagemann, T., et al. (2008). “Re-educating” tumor-associated macrophages by targeting NF-kappaB. Journal of Experimental Medicine, 205(6), 1261–1268.PubMedCentralPubMed
90.
go back to reference Rolny, C., et al. (2011). HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell, 19(1), 31–44.PubMed Rolny, C., et al. (2011). HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell, 19(1), 31–44.PubMed
91.
go back to reference Na, Y. R., et al. (2013). Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One, 8(5), e63451.PubMedCentralPubMed Na, Y. R., et al. (2013). Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One, 8(5), e63451.PubMedCentralPubMed
92.
go back to reference Veltman, J. D., et al. (2010). Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. British Journal of Cancer, 103(5), 629–641.PubMedCentralPubMed Veltman, J. D., et al. (2010). Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. British Journal of Cancer, 103(5), 629–641.PubMedCentralPubMed
93.
go back to reference Coscia, M., et al. (2010). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 14(12), 2803–2815.PubMed Coscia, M., et al. (2010). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 14(12), 2803–2815.PubMed
94.
go back to reference Di Lorenzo, G., Buonerba, C., & Kantoff, P. W. (2011). Immunotherapy for the treatment of prostate cancer. Nature Reviews. Clinical Oncology, 8(9), 551–561.PubMed Di Lorenzo, G., Buonerba, C., & Kantoff, P. W. (2011). Immunotherapy for the treatment of prostate cancer. Nature Reviews. Clinical Oncology, 8(9), 551–561.PubMed
95.
go back to reference Djaafar, S., et al. (2010). Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. Arthritis and Rheumatism, 62(11), 3300–3310.PubMed Djaafar, S., et al. (2010). Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. Arthritis and Rheumatism, 62(11), 3300–3310.PubMed
96.
go back to reference Sawant, A., et al. (2012). Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. Journal of Immunology, 189(9), 4258–4265. Sawant, A., et al. (2012). Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. Journal of Immunology, 189(9), 4258–4265.
97.
go back to reference Zou, W., et al. (2001). Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Medicine, 7(12), 1339–1346.PubMed Zou, W., et al. (2001). Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nature Medicine, 7(12), 1339–1346.PubMed
98.
go back to reference Masopust, D., & Schenkel, J. M. (2013). The integration of T cell migration, differentiation and function. Nature Reviews Immunology, 13(5), 309–320.PubMed Masopust, D., & Schenkel, J. M. (2013). The integration of T cell migration, differentiation and function. Nature Reviews Immunology, 13(5), 309–320.PubMed
99.
go back to reference Fournier, P. G., Chirgwin, J. M., & Guise, T. A. (2006). New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatology, 18(4), 396–404. Fournier, P. G., Chirgwin, J. M., & Guise, T. A. (2006). New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatology, 18(4), 396–404.
100.
go back to reference Nakashima, T., & Takayanagi, H. (2009). Osteoimmunology: crosstalk between the immune and bone systems. Journal of Clinical Immunology, 29(5), 555–567.PubMed Nakashima, T., & Takayanagi, H. (2009). Osteoimmunology: crosstalk between the immune and bone systems. Journal of Clinical Immunology, 29(5), 555–567.PubMed
101.
go back to reference Kiesel, J. R., Buchwald, Z. S., & Aurora, R. (2009). Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. Journal of Immunology, 182(9), 5477–5487. Kiesel, J. R., Buchwald, Z. S., & Aurora, R. (2009). Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. Journal of Immunology, 182(9), 5477–5487.
102.
go back to reference Takayanagi, H. (2010). New immune connections in osteoclast formation. Annals of the New York Academy of Sciences, 1192, 117–123.PubMed Takayanagi, H. (2010). New immune connections in osteoclast formation. Annals of the New York Academy of Sciences, 1192, 117–123.PubMed
103.
go back to reference Zhang, K., et al. (2011). CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Research, 71(14), 4799–4808.PubMedCentralPubMed Zhang, K., et al. (2011). CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Research, 71(14), 4799–4808.PubMedCentralPubMed
104.
go back to reference Bidwell, B. N., et al. (2012). Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature Medicine, 18, 1224–1231. Bidwell, B. N., et al. (2012). Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nature Medicine, 18, 1224–1231.
105.
go back to reference Zhao, E., et al. (2012). Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology, 1(2), 152–161.PubMedCentralPubMed Zhao, E., et al. (2012). Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology, 1(2), 152–161.PubMedCentralPubMed
106.
go back to reference Bidwell, B. N., et al. (2012). Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med, 18(8), 1224–1231.PubMed Bidwell, B. N., et al. (2012). Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med, 18(8), 1224–1231.PubMed
107.
go back to reference Pappalardo, A., Thompson, K. (2013). Activated gammadelta T cells inhibit osteoclast differentiation and resorptive activity in vitro. Clinical and Experimental Immunology, 174, 281–291. Pappalardo, A., Thompson, K. (2013). Activated gammadelta T cells inhibit osteoclast differentiation and resorptive activity in vitro. Clinical and Experimental Immunology, 174, 281–291.
108.
go back to reference Dieli, F., et al. (2003). Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood, 102(6), 2310–2311.PubMed Dieli, F., et al. (2003). Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood, 102(6), 2310–2311.PubMed
109.
go back to reference DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010). Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Reviews, 29(2), 309–316.PubMedCentralPubMed DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010). Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Reviews, 29(2), 309–316.PubMedCentralPubMed
110.
go back to reference Roy, L. D., et al. (2013). Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling. Breast Cancer Research, 15(2), R32.PubMedCentralPubMed Roy, L. D., et al. (2013). Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling. Breast Cancer Research, 15(2), R32.PubMedCentralPubMed
111.
go back to reference Bord, S., et al. (2004). Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. British Journal of Haematology, 126(2), 244–251.PubMed Bord, S., et al. (2004). Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. British Journal of Haematology, 126(2), 244–251.PubMed
112.
go back to reference Kacena, M. A., Gundberg, C. M., & Horowitz, M. C. (2006). A reciprocal regulatory interaction between megakaryocytes, bone cells, and hematopoietic stem cells. Bone, 39(5), 978–984.PubMed Kacena, M. A., Gundberg, C. M., & Horowitz, M. C. (2006). A reciprocal regulatory interaction between megakaryocytes, bone cells, and hematopoietic stem cells. Bone, 39(5), 978–984.PubMed
113.
go back to reference Ciovacco, W. A., et al. (2010). Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation. Journal of Cellular Biochemistry, 109(4), 774–781.PubMedCentralPubMed Ciovacco, W. A., et al. (2010). Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation. Journal of Cellular Biochemistry, 109(4), 774–781.PubMedCentralPubMed
114.
go back to reference Li, X., et al. (2011). Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 26(1), 125–134. Li, X., et al. (2011). Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 26(1), 125–134.
115.
go back to reference Deutsch, V. R., & Tomer, A. (2013). Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. British Journal of Haematology, 161(6), 778–793.PubMed Deutsch, V. R., & Tomer, A. (2013). Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. British Journal of Haematology, 161(6), 778–793.PubMed
116.
go back to reference Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews Cancer, 11(2), 123–134.PubMed Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews Cancer, 11(2), 123–134.PubMed
117.
go back to reference Erpenbeck, L., & Schon, M. P. (2010). Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood, 115(17), 3427–3436.PubMedCentralPubMed Erpenbeck, L., & Schon, M. P. (2010). Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood, 115(17), 3427–3436.PubMedCentralPubMed
118.
go back to reference Karpatkin, S., et al. (1988). Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. The Journal of Clinical Investigation, 81(4), 1012–1019.PubMedCentralPubMed Karpatkin, S., et al. (1988). Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. The Journal of Clinical Investigation, 81(4), 1012–1019.PubMedCentralPubMed
119.
go back to reference Bakewell, S. J., et al. (2003). Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proceedings of the National Academy of Sciences of the United States of America, 100(24), 14205–14210.PubMedCentralPubMed Bakewell, S. J., et al. (2003). Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proceedings of the National Academy of Sciences of the United States of America, 100(24), 14205–14210.PubMedCentralPubMed
120.
go back to reference Sottnik, J. L., et al. (2013). Integrin alpha2beta 1 (alpha2beta1) promotes prostate cancer skeletal metastasis. Clinical and Experimental Metastasis, 30(5), 569–578.PubMedCentralPubMed Sottnik, J. L., et al. (2013). Integrin alpha2beta 1 (alpha2beta1) promotes prostate cancer skeletal metastasis. Clinical and Experimental Metastasis, 30(5), 569–578.PubMedCentralPubMed
121.
go back to reference Gupta, A., Cao, W., & Chellaiah, M. A. (2012). Integrin alphavbeta3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-kappaB ligand signaling axis. Molecular Cancer, 11, 66.PubMedCentralPubMed Gupta, A., Cao, W., & Chellaiah, M. A. (2012). Integrin alphavbeta3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-kappaB ligand signaling axis. Molecular Cancer, 11, 66.PubMedCentralPubMed
122.
go back to reference King, T. E., et al. (2008). The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One, 3(10), e3535.PubMedCentralPubMed King, T. E., et al. (2008). The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One, 3(10), e3535.PubMedCentralPubMed
123.
go back to reference Kerr, B. A., et al. (2013) Platelets govern pre-metastatic tumor communication to bone. Oncogene, 32, 4319–4324. Kerr, B. A., et al. (2013) Platelets govern pre-metastatic tumor communication to bone. Oncogene, 32, 4319–4324.
124.
go back to reference Mantyh, P. W., et al. (2002). Molecular mechanisms of cancer pain. Nature Reviews Cancer, 2(3), 201–209.PubMed Mantyh, P. W., et al. (2002). Molecular mechanisms of cancer pain. Nature Reviews Cancer, 2(3), 201–209.PubMed
125.
go back to reference Elefteriou, F. (2008). Regulation of bone remodeling by the central and peripheral nervous system. Archives of Biochemistry and Biophysics, 473(2), 231–236.PubMedCentralPubMed Elefteriou, F. (2008). Regulation of bone remodeling by the central and peripheral nervous system. Archives of Biochemistry and Biophysics, 473(2), 231–236.PubMedCentralPubMed
126.
go back to reference Yoneda, T., et al. (2011). Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone, 48(1), 100–105.PubMed Yoneda, T., et al. (2011). Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone, 48(1), 100–105.PubMed
127.
go back to reference Magnon, C., et al. (2013). Autonomic nerve development contributes to prostate cancer progression. Science, 341(6142), 1236361.PubMed Magnon, C., et al. (2013). Autonomic nerve development contributes to prostate cancer progression. Science, 341(6142), 1236361.PubMed
128.
go back to reference Mistry, T., et al. (2007). Obesity and prostate cancer: a role for adipokines. European Urology, 52(1), 46–53.PubMed Mistry, T., et al. (2007). Obesity and prostate cancer: a role for adipokines. European Urology, 52(1), 46–53.PubMed
129.
go back to reference Campbell, J. P., et al. (2012). Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biology, 10(7), e1001363.PubMedCentralPubMed Campbell, J. P., et al. (2012). Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biology, 10(7), e1001363.PubMedCentralPubMed
130.
go back to reference Kondo, H., Takeuchi, S., & Togari, A. (2013). beta-Adrenergic signaling stimulates osteoclastogenesis via reactive oxygen species. American Journal of Physiology, Endocrinology and Metabolism, 304(5), E507–E515. Kondo, H., Takeuchi, S., & Togari, A. (2013). beta-Adrenergic signaling stimulates osteoclastogenesis via reactive oxygen species. American Journal of Physiology, Endocrinology and Metabolism, 304(5), E507–E515.
131.
go back to reference Hassan, S., et al. (2013). Behavioral stress accelerates prostate cancer development in mice. The Journal of Clinical Investigation, 123(2), 874–886.PubMedCentralPubMed Hassan, S., et al. (2013). Behavioral stress accelerates prostate cancer development in mice. The Journal of Clinical Investigation, 123(2), 874–886.PubMedCentralPubMed
132.
go back to reference Grytli, H. H., et al. (2013). Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate, 73(3), 250–260.PubMed Grytli, H. H., et al. (2013). Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate, 73(3), 250–260.PubMed
133.
go back to reference Macklin, P., & Lowengrub, J. (2007). Nonlinear simulation of the effect of microenvironment on tumor growth. Journal of Theoretical Biology, 245(4), 677–704.PubMed Macklin, P., & Lowengrub, J. (2007). Nonlinear simulation of the effect of microenvironment on tumor growth. Journal of Theoretical Biology, 245(4), 677–704.PubMed
134.
go back to reference Nagl, S. (2005). Cancer bioinformatics: from therapy design to treatment. Chichester: Wiley. Nagl, S. (2005). Cancer bioinformatics: from therapy design to treatment. Chichester: Wiley.
135.
go back to reference Wodarz, D., & Komarova, N. L. (2008). Computational biology of cancer: lecture notes and mathematical modeling. Hackensack: World Scientific. Wodarz, D., & Komarova, N. L. (2008). Computational biology of cancer: lecture notes and mathematical modeling. Hackensack: World Scientific.
136.
go back to reference Macal, C. M., & North, M. J. (2010). Tutorial on agent-based modelling and simulation. Journal of Simulation, 4(3), 151–162. Macal, C. M., & North, M. J. (2010). Tutorial on agent-based modelling and simulation. Journal of Simulation, 4(3), 151–162.
137.
go back to reference Wolfram, S. (2002). A new kind of science. Champaign: Wolfram Media. Wolfram, S. (2002). A new kind of science. Champaign: Wolfram Media.
138.
go back to reference Ribba, B., et al. (2004). The use of hybrid cellular automaton models for improving cancer therapy. Lecture Notes in Computer Science, 3305, 444–53. Ribba, B., et al. (2004). The use of hybrid cellular automaton models for improving cancer therapy. Lecture Notes in Computer Science, 3305, 444–53.
139.
go back to reference Anderson, A. R. A., Chaplain, M. A. J., & Rejniak, K. A. (2007). Single-cell-based models in biology and medicine. Basel: Birkhäuser. Anderson, A. R. A., Chaplain, M. A. J., & Rejniak, K. A. (2007). Single-cell-based models in biology and medicine. Basel: Birkhäuser.
140.
go back to reference Basanta, D., et al. (2009). The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. Cancer Research, 69(17), 7111–7120.PubMedCentralPubMed Basanta, D., et al. (2009). The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. Cancer Research, 69(17), 7111–7120.PubMedCentralPubMed
141.
go back to reference Pivonka, P., & Komarova, S. V. (2010). Mathematical modeling in bone biology: from intracellular signaling to tissue mechanics. Bone, 47(2), 181–189.PubMed Pivonka, P., & Komarova, S. V. (2010). Mathematical modeling in bone biology: from intracellular signaling to tissue mechanics. Bone, 47(2), 181–189.PubMed
142.
go back to reference Ryser, M. D., Nigam, N., & Komarova, S. V. (2009). Mathematical modeling of spatio-temporal dynamics of a single bone multicellular unit. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 24(5), 860–870. Ryser, M. D., Nigam, N., & Komarova, S. V. (2009). Mathematical modeling of spatio-temporal dynamics of a single bone multicellular unit. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 24(5), 860–870.
143.
go back to reference Ryser, M. D., Qu, Y., & Komarova, S. V. (2012). Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Computational Biology, 8(10), e1002703.PubMedCentralPubMed Ryser, M. D., Qu, Y., & Komarova, S. V. (2012). Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Computational Biology, 8(10), e1002703.PubMedCentralPubMed
Metadata
Title
Integrating new discoveries into the “vicious cycle” paradigm of prostate to bone metastases
Authors
Leah M. Cook
Gemma Shay
Arturo Aruajo
Conor C. Lynch
Publication date
01-09-2014
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2-3/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-014-9494-4

Other articles of this Issue 2-3/2014

Cancer and Metastasis Reviews 2-3/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine